Worktype E5 - PHARMACEUTICAL FORMULATION OF

Worktype Details

CodeE5
NamePHARMACEUTICAL FORMULATION OF

Experiments (200 results)

Filters
Worktypes (39)
200
109
44
35
29
24
12
12
11
10
10
9
9
8
8
7
7
5
4
4
3
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
No match
Pharmacology (33)
7
7
4
4
3
3
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
141
No match
Compounds (162)
15
8
7
7
6
6
6
5
5
5
5
5
5
4
4
4
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
24
No match
Organisms (183)
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
No match
200 experiments
No experiment matches the selected filters.
ExperimentWorktypesPharmacologyOrganism (specimen)Compound
321635
PATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
GENTAMICINNEBRAMYCINNEOMYCINERYTHROMYCIN
323631
PHARMACOLOGY OF COMPOUND - IN VITROPHEROMONE MARKER CODEPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
PHEROMONE(INSECT SEX ATTRACTANT)
Empty organism
ANISALDEHYDEPHENYLACETIC ACIDCINNAMYL ALCOHOLCINNAMALDEHYDEPHENYLETHYL ALCOHOL,BETA:CINNAMIC ACIDSALICYLIC ACIDBENZYL ALCOHOLPHENOL,SEC-BUTYL:EUGENOLPIPERONALBENZYL ACETONEIONONE,METHYL:SAFROLEACETOPHENONE
330196
STABILITY STUDIES OFPHARMACEUTICAL FORMULATION OF
Empty organism
GLYCEROL
328954
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANSISOLATION AND IDENTIFICATION OF
ANTIULCER ACTIVITY
Penicillium canadense (HYPHOMYCETES)
CANADENSOLIDE,DIHYDRO:
326323
WORK DESCRIBED MAINLY CONCERNS METHODOLOGYANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
BIOMYCIN
320850
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPREPARATION OF DERIVATIVES OF
Empty organism
VITAMIN B-1NICOTINAMIDELACTOSEASCORBIC ACID
321150
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFANTICANCER AND/OR CYTOTOXICITY MARKER CODE
Empty organism
ABRIN
327569
EFFECTS DUE TO A COMBINATION OF DRUGSPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANS
HYPOGLYCEMIC ACTIVITY
Empty organism
ERGOTAMINE,DIHYDRO:
330088
PATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OFBIOASSAYPHARMACOLOGY OF COMPOUND - IN HUMANS
ANTIHYPERTENSIVE ACTIVITY
Empty organism
ASCOFURANONE
319205
STABILITY STUDIES OFPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
VITAMIN B-1NICOTINAMIDEFOLIC ACIDVITAMIN B-2VITAMIN B-12VITAMIN B-6
618460
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFANTICANCER AND/OR CYTOTOXICITY MARKER CODE
Lentinus edodes (TRICHOLOMATACEAE)
LENTINAN
1324724
PHARMACOLOGY OF EXTRACT - IN VIVOEFFECTS DUE TO A COMBINATION OF DRUGSPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
ANTIVIRAL ACTIVITY
Hazunta species (APOCYNACEAE)
321488
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
XYLITOL
325586
PATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OFPREPARATION OF DERIVATIVES OF
Empty organism
ERYTHROMYCIN
322979
DISSOLUTION STUDIES OFPHARMACEUTICAL FORMULATION OF
Empty organism
ASCORBIC ACID
321129
EFFECTS DUE TO A COMBINATION OF DRUGSANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANS
IRRITANT ACTIVITY
Empty organism
TETRACYCLINE,OXY:
324901
STABILITY STUDIES OFPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
TOCOPHEROL,ALPHA:
330234
EFFECTS DUE TO A COMBINATION OF DRUGSPATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANS
ANTIFUNGAL ACTIVITY
Empty organism
THYMOLHINOKITIOLUNDECANOIC ACID
321140
PATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OFSOLUBILITY STUDIES OF
Empty organism
TETRACYCLINE,OXY:
330295
STABILITY STUDIES OFPHARMACEUTICAL FORMULATION OF
Empty organism
STREPTOKINASE
408029
PHARMACOLOGY OF COMPOUND - IN VIVOPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFANTICANCER AND/OR CYTOTOXICITY MARKER CODE
ANTITUMOR ACTIVITY
Empty organism
ACRONYCINE
330041
EFFECTS DUE TO A COMBINATION OF DRUGSPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFANTICANCER AND/OR CYTOTOXICITY MARKER CODE
Empty organism
VITAMIN B-1AMYGDALIN
330363
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
ASCORBIC ACID
617597
PHARMACOLOGY OF COMPOUND - IN VIVOPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
HYPOTENSIVE ACTIVITY
Empty organism
STEPHARINE
319184
LIQUID-LIQUID SEPARATION MARKER CODEPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
ASCORBIC ACID
318710
PHARMACEUTICAL FORMULATION OF
Empty organism
CHOLESTERYL ACETATESITOSTEROL,BETA:CHOLESTEROL
319158
EFFECTS DUE TO A COMBINATION OF DRUGSPATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
KASUGAMYCINCHLORAMPHENICOLPENICILLIN G
325584
STABILITY STUDIES OFPATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
TETRACYCLINE,OXY:
325864
PHARMACEUTICAL FORMULATION OFREVIEW OF
Empty organism
VITAMIN B-12
325605
STABILITY STUDIES OFPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
DIGOXIN,BETA-ACETYL:*
409307
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANS
SWEETENING EFFECT
Empty organism
XYLITOL
325739
PHARMACOLOGY OF COMPOUND - IN VITROANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
ANTIBACTERIAL ACTIVITY
Empty organism
UNDECYLENIC ACID
319271
PHARMACEUTICAL FORMULATION OFREVIEW OF
Empty organism
CHOLESTEROL
329185
PHARMACEUTICAL FORMULATION OFABSORPTION/DISTRIBUTION STUDY
Empty organism
PILOCARPINE
326195
PHARMACEUTICAL FORMULATION OFREVIEW OF
Empty organism
INSULIN
321537
STABILITY STUDIES OFPATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
TETRACYCLINE,CHLOR:
325494
PATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
CHLORAMPHENICOL
321134
STABILITY STUDIES OFPHARMACEUTICAL FORMULATION OF
Empty organism
ASCORBIC ACID
319114
PHARMACEUTICAL FORMULATION OF
Empty organism
NICOTINAMIDEPAPAVERINE
330216
STABILITY STUDIES OFPHARMACEUTICAL FORMULATION OF
Empty organism
MANNITOL
320072
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANS
CHOLERETIC ACTIVITY
Empty organism
SORBITOLLACTULOSE
325667
DISSOLUTION STUDIES OFPHARMACEUTICAL FORMULATION OFSOLUBILITY STUDIES OF
Empty organism
CAFFEINE
326312
ANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OFANTICANCER AND/OR CYTOTOXICITY MARKER CODE
ANTIYEAST ACTIVITY
Empty organism
USNIC ACID
319075
PATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OFPREPARATION OF DERIVATIVES OF
Empty organism
CHLORAMPHENICOL
322699
EFFECTS DUE TO A COMBINATION OF DRUGSPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF EXTRACT - IN HUMANS
ANTIHEMORRHOIDAL ACTIVITY
Angelica species (APIACEAE)
319375
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
INSULIN
328118
DISSOLUTION STUDIES OFSTABILITY STUDIES OFPHARMACEUTICAL FORMULATION OFABSORPTION/DISTRIBUTION STUDY
Empty organism
DIGOXIN
1007783
PHARMACEUTICAL FORMULATION OF
Salvia miltiorrhiza (LAMIACEAE)
321251
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
VITAMIN B-1VITAMIN AVITAMIN B-2NICOTINIC ACIDVITAMIN B-6ASCORBIC ACID
326313
ANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OFANTICANCER AND/OR CYTOTOXICITY MARKER CODE
ANTIFUNGAL ACTIVITY
Empty organism
USNIC ACID
319151
ANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
PENICILLIN G
330352
STABILITY STUDIES OFCHEMICAL DEGRADATION OFPHARMACEUTICAL FORMULATION OF
Empty organism
ATROPINE
617607
PHARMACOLOGY OF COMPOUND - IN VIVOPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
GLUTAMATE-PYRUVATE-TRANSAMINASE INHIBITION
Empty organism
PUTRESCINE
617459
PHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANSREVIEW OF
KERATOLYTIC EFFECT
Symphytum officinale (BORAGINACEAE)
ALLANTOIN
322697
EFFECTS DUE TO A COMBINATION OF DRUGSPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF EXTRACT - IN HUMANS
ANTIHEMORRHOIDAL ACTIVITY
Aesculus hippocastanum (HIPPOCASTANACEAE)
320960
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
VITAMIN B-2ASCORBIC ACID
325472
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
TRAGACANTH GUMCELLULOSE
330235
PHARMACOLOGY OF COMPOUND - IN VIVOEFFECTS DUE TO A COMBINATION OF DRUGSPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
VASODILATOR ACTIVITY
Empty organism
ERGOCRISTINE,DIHYDRO:VINCAMINE
326194
STABILITY STUDIES OFPHARMACEUTICAL FORMULATION OF
Empty organism
ASCORBIC ACID
331467
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFABSORPTION/DISTRIBUTION STUDY
Empty organism
DIGOXIN
330238
PHARMACEUTICAL FORMULATION OF
Empty organism
GLYCYRRHETINIC ACID
339702
STABILITY STUDIES OFPHARMACEUTICAL FORMULATION OF
Empty organism
CODEINE
767021
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Aloe vera (LILIACEAE)
323139
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF EXTRACT - IN HUMANS
COSMETIC EFFECTS
Aloe vera (LILIACEAE)
326320
DISSOLUTION STUDIES OFPHARMACEUTICAL FORMULATION OF
Empty organism
TRAGACANTH GUM
321663
PHARMACEUTICAL FORMULATION OFTLC DATA REPORTEDREVIEW OF
Empty organism
BOLDINEGLAUCINE,(+):MAGNOFLORINE
409308
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Vinca minor (APOCYNACEAE)
VINCAMINE
319284
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANS
ANTIOBESITY ACTIVITY
Empty organism
CAFFEINE
614722
STABILITY STUDIES OFPATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OFSOLUBILITY STUDIES OF
Empty organism
CHELOCARDIN
326278
STABILITY STUDIES OFPHARMACEUTICAL FORMULATION OF
Empty organism
VITAMIN B-1VITAMIN B-12VITAMIN B-6
319363
PHARMACEUTICAL FORMULATION OF
Digitalis species (SCROPHULARIACEAE)
321489
COMPLEX FORMATIONPATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
CEFAZOLIN*
1016641
PHARMACEUTICAL FORMULATION OFISOLATION AND IDENTIFICATION OF
Cocculus trilobus (MENISPERMACEAE)
TRILOBINE,ISO:TRILOBINE
321183
PHARMACEUTICAL ANALYSIS OFSTABILITY STUDIES OFIDENTIFICATION OFQUANTITATIVE DATA REPORTEDPHARMACEUTICAL FORMULATION OF
Empty organism
GLAUCINE,(+):
323630
PHARMACOLOGY OF COMPOUND - IN VITROPHEROMONE MARKER CODEPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
PHEROMONE(SIGNALLING)
Empty organism
ANISALDEHYDEPHENYLACETIC ACIDCINNAMYL ALCOHOLCINNAMALDEHYDEPHENYLETHYL ALCOHOL,BETA:CINNAMIC ACIDSALICYLIC ACIDBENZYL ALCOHOLPHENOL,SEC-BUTYL:EUGENOLPIPERONALBENZYL ACETONEIONONE,METHYL:SAFROLEACETOPHENONE
330150
EFFECTS DUE TO A COMBINATION OF DRUGSPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF EXTRACT - IN HUMANS
EMOLLIENT EFFECT
Hypericum perforatum (CLUSIACEAE)
408030
PHARMACOLOGY OF COMPOUND - IN VIVOPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFANTICANCER AND/OR CYTOTOXICITY MARKER CODE
ANTITUMOR ACTIVITY
Empty organism
ACRONYCINE
320877
COMPLEX FORMATIONPHARMACEUTICAL FORMULATION OF
Empty organism
CHONDROITINDEXTRAN
329909
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
PAPAVERINE
328119
PHARMACEUTICAL FORMULATION OF
Empty organism
PAPAVERINE
326172
EFFECTS DUE TO A COMBINATION OF DRUGSPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANS
HAIR STIMULANT EFFECT
Empty organism
ERUCIC ACIDMYRISTIC ACIDCITRONELLOL,(-):
325453
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANS
KERATOLYTIC EFFECT
Empty organism
ADENOSINE
742613
PHARMACEUTICAL FORMULATION OF
Panax ginseng (ARALIACEAE)
325053
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
INSULIN
319240
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
OLEIC ACID
322683
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANS
LAXATIVE EFFECT
Empty organism
TRAGACANTH GUM
617462
PHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANSREVIEW OF
KERATOLYTIC EFFECT
Symphytum officinale (BORAGINACEAE)
ALLANTOIN
329272
PHARMACEUTICAL FORMULATION OF
Empty organism
QUININE
331445
PHARMACEUTICAL ANALYSIS OFWORK DESCRIBED MAINLY CONCERNS METHODOLOGYQUANTITATIVE DATA REPORTEDPHARMACEUTICAL FORMULATION OFTLC DATA REPORTED
Empty organism
VITAMIN ATOCOPHEROL,ALPHA:
742644
PHARMACEUTICAL FORMULATION OF
Panax ginseng (ARALIACEAE)
324915
PHARMACOLOGY OF COMPOUND - IN VIVOSTABILITY STUDIES OFCOMPLEX FORMATIONANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
ERYTHROMYCIN
319154
PATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
NEOMYCIN
322700
EFFECTS DUE TO A COMBINATION OF DRUGSPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF EXTRACT - IN HUMANS
ANTIHEMORRHOIDAL ACTIVITY
Althaea species (MALVACEAE)
331268
ANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
CHLORAMPHENICOL
1324723
EFFECTS DUE TO A COMBINATION OF DRUGSCLINICAL STUDIESPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
ANTIVIRAL ACTIVITY
Hazunta species (APOCYNACEAE)
321894
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANS
VASODILATOR ACTIVITY
Empty organism
TABERNAEMONTANINE
321630
STABILITY STUDIES OFCOMPLEX FORMATIONPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANSPREPARATION OF DERIVATIVES OF
ANTIHEPATOTOXIC ACTIVITY
Empty organism
SILYCHRISTINSILYBINSILYDIANIN
330214
STABILITY STUDIES OFPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
PROSTAGLANDIN E-3PROSTAGLANDIN E-2
330348
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
PILOCARPINE
320071
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANS
LAXATIVE EFFECT
Empty organism
SORBITOLLACTULOSE
323138
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF EXTRACT - IN HUMANS
EMOLLIENT EFFECT
Aloe vera (LILIACEAE)
405302
PHARMACEUTICAL FORMULATION OFANTICANCER AND/OR CYTOTOXICITY MARKER CODE
Empty organism
ACRONYCINE
331007
STABILITY STUDIES OFANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
VIRGINIAMYCIN
330281
GC DATA REPORTEDPHARMACEUTICAL ANALYSIS OFQUANTITATIVE DATA REPORTEDPHARMACEUTICAL FORMULATION OF
Empty organism
MENTHOLCAMPHORCINEOL,1-8:
329294
PHARMACEUTICAL ANALYSIS OFSTABILITY STUDIES OFPHARMACEUTICAL FORMULATION OF
Empty organism
LANATOSIDE ALANATOSIDE B
328047
PHARMACEUTICAL ANALYSIS OFIDENTIFICATION OFQUANTITATIVE DATA REPORTEDPHARMACEUTICAL FORMULATION OFINDICATION BY COLOR REACTIONS
Empty organism
DIGOXIN
325844
WORK DESCRIBED MAINLY CONCERNS METHODOLOGYIDENTIFICATION OFQUANTITATIVE DATA REPORTEDPHARMACEUTICAL FORMULATION OF
Empty organism
ASCORBIC ACID,DEHYDRO: L:GULONIC ACID,2-3-DIKETO: L:ASCORBIC ACID
322696
EFFECTS DUE TO A COMBINATION OF DRUGSPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF EXTRACT - IN HUMANS
ANTIHEMORRHOIDAL ACTIVITY
Hamamelis species (HAMAMELIDACEAE)
320961
PATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
CANDICIDIN
319520
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFABSORPTION/DISTRIBUTION STUDY
Empty organism
DIGOXIN
326277
STABILITY STUDIES OFPHARMACEUTICAL FORMULATION OF
Empty organism
METHIONINETRYPTOPHAN
325495
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
PROGESTERONEPILOCARPINE
325740
PHARMACOLOGY OF COMPOUND - IN VITROANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
ANTIFUNGAL ACTIVITY
Empty organism
UNDECYLENIC ACID
321149
PATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
PENICILLIN V
329275
STABILITY STUDIES OFPHARMACEUTICAL FORMULATION OF
Empty organism
SCOPOLAMINE
328852
DISSOLUTION STUDIES OFPHARMACEUTICAL FORMULATION OFPHYSICAL CHARACTERISTICS OF FORMULATIONS
Empty organism
ASCORBIC ACID
325471
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
PENICILLAMINE,D:
319272
PHARMACEUTICAL FORMULATION OFREVIEW OF
Empty organism
CHOLESTEROL
612497
PHARMACEUTICAL FORMULATION OF
Panax ginseng (ARALIACEAE)
320876
COMPLEX FORMATIONPATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
STREPTOMYCIN
329643
PATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OFPREPARATION OF DERIVATIVES OF
Empty organism
GENTAMICIN
409306
COMPLEX FORMATIONPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
ALLANTOIN
324910
PHARMACEUTICAL ANALYSIS OFWORK DESCRIBED MAINLY CONCERNS METHODOLOGYRADIOIMMUNOASSAY USEDQUANTITATIVE DATA REPORTEDPHARMACEUTICAL FORMULATION OFABSORPTION/DISTRIBUTION STUDY
Empty organism
DIGOXINTHEOPHYLLINETHEOBROMINE
322682
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANSPREPARATION OF DERIVATIVES OF
PARASYMPATHOLYTIC ACTIVITY
Empty organism
CORYDALINE,(+):
325454
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
GLYCEROLTHEOPHYLLINE
325054
PHARMACEUTICAL FORMULATION OF
Empty organism
CODEINE
319183
LIQUID-LIQUID SEPARATION MARKER CODEPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
ASCORBIC ACID
329607
PATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
LATERIOMYCIN F
325809
PHARMACEUTICAL FORMULATION OF
Empty organism
NICOTINAMIDE
325759
PHARMACOLOGY OF COMPOUND - IN VITROANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
ANTIBACTERIAL ACTIVITY
Empty organism
CHLORAMPHENICOLLINCOMYCIN
321539
PATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OFANTICANCER AND/OR CYTOTOXICITY MARKER CODE
Empty organism
LEUCOMYCIN A-4,TETRAHYDRO:
322695
EFFECTS DUE TO A COMBINATION OF DRUGSPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF EXTRACT - IN HUMANS
ANTIHEMORRHOIDAL ACTIVITY
Juniperus species (CUPRESSACEAE)
1013482
STABILITY STUDIES OFPHARMACEUTICAL FORMULATION OF
Empty organism
PILOCARPINE
319149
PATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
ERYTHROMYCIN
322701
EFFECTS DUE TO A COMBINATION OF DRUGSPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANS
ANTIHEMORRHOIDAL ACTIVITY
Althaea species (MALVACEAE)
VITAMIN B-1AESCULETINRUTIN
325569
PATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
TETRACYCLINE,OXY:NEOMYCIN
408311
STABILITY STUDIES OFPHARMACEUTICAL FORMULATION OF
Empty organism
DOPA,L:
329359
STABILITY STUDIES OFPHARMACEUTICAL FORMULATION OF
Empty organism
ASCORBIC ACID
319194
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
NICOTINIC ACID
330565
EFFECTS DUE TO A COMBINATION OF DRUGSPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANS
SWEETENING EFFECT
Empty organism
POLYSACCHARIDELEVULOSEMALTOSEGLUCOSE,D:
617461
PHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANSREVIEW OF
EMOLLIENT EFFECT
Symphytum officinale (BORAGINACEAE)
ALLANTOIN
329650
PATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
TETRACYCLINE,OXY:
331446
DISSOLUTION STUDIES OFPHARMACEUTICAL FORMULATION OF
Empty organism
CAFFEINE
321862
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANS
ANTISNORING EFFECT
Empty organism
ARECOLINE
325056
PATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
HETACILLIN*
328116
DISSOLUTION STUDIES OFPHARMACEUTICAL FORMULATION OFABSORPTION/DISTRIBUTION STUDY
Empty organism
DIGOXIN
742130
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
CAMPTOTHECIN
330349
DISSOLUTION STUDIES OFPHARMACEUTICAL FORMULATION OFPHYSICAL CHARACTERISTICS OF FORMULATIONS
Empty organism
QUININE
319210
PHARMACEUTICAL FORMULATION OFABSORPTION/DISTRIBUTION STUDY
Empty organism
ASCORBIC ACID
327507
EFFECTS DUE TO A COMBINATION OF DRUGSPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANS
ANTIARRHYTHMIC ACTIVITY
Empty organism
CARNITINE
319138
LIQUID-LIQUID SEPARATION MARKER CODEPATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
CHOLINE,PHOSPHATIDYL:AZULENE
329955
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF EXTRACT - IN HUMANS
ANTIULCER ACTIVITY
Lactobacillus bulgaricus (LACTOBACILLACEAE)
328235
PHARMACEUTICAL FORMULATION OF
Empty organism
ECHINOPSINE
326535
PHARMACOKINETIC/BIOAVAILABITY STUDYPHARMACEUTICAL FORMULATION OF
Empty organism
TOCOPHEROL,ALPHA:
323892
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
GLYCYRRHETINIC ACID
321137
DISSOLUTION STUDIES OFPHARMACEUTICAL ANALYSIS OFPHARMACEUTICAL FORMULATION OF
Empty organism
DIGOXIN
729494
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Ginkgo biloba (GINKGOACEAE)
341131
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
FRUCTOSEMALTITOL
321490
COMPLEX FORMATIONPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
CHOLESTEROL
318628
DISSOLUTION STUDIES OFCHEMICAL CONVERSION OFANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
LEUCOMYCIN A-5
324909
PHARMACOLOGY OF COMPOUND - IN VIVOANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
ANTIBACTERIAL ACTIVITY
Empty organism
AMPICILLIN*
318626
PATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
LEUCOMYCINAMPICILLIN*CHLORAMPHENICOLPENICILLIN GERYTHROMYCIN
326366
EFFECTS DUE TO A COMBINATION OF DRUGSPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANS
ANTIBACTERIAL ACTIVITY
Empty organism
ERGONORCORNINE,9-10-DIHYDRO:DOPA,L:ERGOCORNINEERGOCRYPTINE,ALPHA: 2-BROMO:*
404941
PHARMACEUTICAL FORMULATION OFABSORPTION/DISTRIBUTION STUDY
Empty organism
THEOPHYLLINE
325473
STABILITY STUDIES OFPHARMACEUTICAL FORMULATION OFREVIEW OF
Empty organism
762181
PHARMACEUTICAL FORMULATION OF
Hypericum perforatum (CLUSIACEAE)
325470
ANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OFANTICANCER AND/OR CYTOTOXICITY MARKER CODE
Empty organism
DAUNORUBICIN
325088
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANS
GALLSTONE SOLUBILIZING EFFECT
Empty organism
CHOLIC ACID,CHENO-DEOXY:
322681
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANSPREPARATION OF DERIVATIVES OF
ANTIULCER ACTIVITY
Empty organism
CORYDALINE,(+):
325884
STABILITY STUDIES OFPHARMACEUTICAL FORMULATION OFPAPER CHROMATOGRAPHY DATA REPORTED
Empty organism
VITAMIN B-2
324920
PHARMACEUTICAL FORMULATION OFABSORPTION/DISTRIBUTION STUDY
Empty organism
NICOTINE
324905
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
MYRISTIC ACIDSTEARIC ACIDPALMITIC ACIDLAURIC ACID
766269
IDENTIFICATION IN BY HPLCQUANTITATIVE DATA REPORTEDPHARMACEUTICAL FORMULATION OF
Panax ginseng (ARALIACEAE)
GINSENOSIDE RB-1
329296
PHARMACEUTICAL ANALYSIS OFWORK DESCRIBED MAINLY CONCERNS METHODOLOGYIDENTIFICATION OFQUANTITATIVE DATA REPORTEDPHARMACEUTICAL FORMULATION OFINDICATION BY COLOR REACTIONS
Empty organism
ASCORBIC ACID
324917
PHARMACOLOGY OF COMPOUND - IN VIVOEFFECTS DUE TO A COMBINATION OF DRUGSSTABILITY STUDIES OFCOMPLEX FORMATIONANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
ANTIMICROBIAL ACTIVITY(UNSPECIFIED)
Empty organism
ERYTHROMYCIN
321151
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFANTICANCER AND/OR CYTOTOXICITY MARKER CODE
Empty organism
RICIN
330294
STABILITY STUDIES OFCHEMICAL DEGRADATION OFPHARMACEUTICAL FORMULATION OF
Empty organism
ATROPINE
329226
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
ATROPINE
335278
PHARMACOLOGY OF COMPOUND - IN VIVOWORK DESCRIBED MAINLY CONCERNS METHODOLOGYCOMPLEX FORMATIONANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OFTOXICITY REPORTED
ANTIBACTERIAL ACTIVITY
Empty organism
PRODIGIOSAN
321133
DISSOLUTION STUDIES OFSTABILITY STUDIES OFPHARMACEUTICAL FORMULATION OF
Empty organism
RESERPINE
326316
EFFECTS DUE TO A COMBINATION OF DRUGSPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANS
ANTIBACTERIAL ACTIVITY
Empty organism
SORBIC ACID
324906
EFFECTS DUE TO A COMBINATION OF DRUGSPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANS
BITTER TASTING EFFECT
Empty organism
BERBERINE
325055
PHARMACEUTICAL FORMULATION OF
Empty organism
COD LIVER OIL
332730
PHARMACOLOGY OF COMPOUND - IN VIVOPATENT DESCRIBEDANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
ANTIFUNGAL ACTIVITY
Empty organism
SICCANIN
330016
STABILITY STUDIES OFPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
PROTEASE
321538
STABILITY STUDIES OFPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
PANTOTHENIC ACIDVITAMIN K-4VITAMIN B-1NICOTINAMIDEFOLIC ACIDVITAMIN AVITAMIN B-2VITAMIN D-3VITAMIN B-12VITAMIN B-6BENZOIC ACID,2-5-DIHYDROXY:TOCOPHEROL,ALPHA:
325727
PHARMACEUTICAL FORMULATION OFREVIEW OF
Empty organism
323140
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFMEDICINAL FOLKLORE REPORTED FOR
ANTIVENIN EFFECT
Aloe vera (LILIACEAE)
329585
PATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Empty organism
PROSTAGLANDIN E-1
341182
PHARMACEUTICAL FORMULATION OFREVIEW OF
Empty organism
PANCREATIN
326311
ANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OFANTICANCER AND/OR CYTOTOXICITY MARKER CODE
ANTIBACTERIAL ACTIVITY
Empty organism
USNIC ACID
322698
EFFECTS DUE TO A COMBINATION OF DRUGSPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF EXTRACT - IN HUMANS
ANTIHEMORRHOIDAL ACTIVITY
Gentiana species (GENTIANACEAE)
328117
STABILITY STUDIES OFPHARMACEUTICAL FORMULATION OF
Empty organism
PILOCARPINE
325521
EFFECTS DUE TO A COMBINATION OF DRUGSPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANS
ANOREXIC ACTIVITY
Empty organism
XANTHAN GUMVITAMIN B-1NICOTINAMIDEVITAMIN AVITAMIN B-2VITAMIN B-12ASCORBIC ACIDTOCOPHEROL,ALPHA:
762179
PHARMACEUTICAL FORMULATION OF
Empty organism
ASIATICOSIDE
763580
PHARMACEUTICAL FORMULATION OF A PLANTPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OF
Echinacea species (ASTERACEAE)
325133
WORK DESCRIBED MAINLY CONCERNS METHODOLOGYANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)PHARMACEUTICAL FORMULATION OF
Empty organism
CHLORAMPHENICOL
617460
PHARMACEUTICAL FORMULATION OFPHARMACOLOGY OF COMPOUND - IN HUMANSREVIEW OF
EMOLLIENT EFFECT
Symphytum officinale (BORAGINACEAE)
ALLANTOIN
330382
STABILITY STUDIES OFPATENT DESCRIBEDPHARMACEUTICAL FORMULATION OFSOLUBILITY STUDIES OF
Empty organism
VITAMIN A
331439
PHARMACEUTICAL FORMULATION OF
Empty organism
ATROPINE
Show SPARQL Queries (1)